{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:29:52Z","timestamp":1792772992341,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005624","name":"Medizinischen Hochschule Hannover","doi-asserted-by":"publisher","award":["10806_BO_K_2023"],"award-info":[{"award-number":["10806_BO_K_2023"]}],"id":[{"id":"10.13039\/501100005624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.fr","clinicalkey.jp","jprasopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JPRAS Open"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jpra.2025.02.003","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T02:58:52Z","timestamp":1738983532000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Stevens\u2013Johnson Syndrome and Toxic Epidermal Necrolysis: A 15-year Regional Burn Center Experience"],"prefix":"10.1016","volume":"44","author":[{"given":"Dima","family":"Obed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Dastagir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicco","family":"Krezdorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doha","family":"Obed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpra.2025.02.003_bib0001","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.alit.2016.06.001","article-title":"A review of toxic epidermal necrolysis management in Japan","volume":"66","author":"Kinoshita","year":"2017","journal-title":"Allergology Int"},{"key":"10.1016\/j.jpra.2025.02.003_bib0002","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjd.18424","article-title":"Incidence of and mortality from epidermal necrolysis (Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis) in France during 2003\u201316: A four-source capture\u2013recapture estimate","volume":"182","author":"Chaby","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0003","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/wound.2019.0977","article-title":"Toxic epidermal necrolysis and Steven\u2013Johnson syndrome: A comprehensive review","volume":"9","author":"Charlton","year":"2020","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"10.1016\/j.jpra.2025.02.003_bib0004","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.burns.2017.10.022","article-title":"Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results","volume":"44","author":"Papp","year":"2018","journal-title":"Burns"},{"key":"10.1016\/j.jpra.2025.02.003_bib0005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/pds.3937","article-title":"Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry: Incidence of SJS and TEN in northern Italy","volume":"25","author":"Diphoorn","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jpra.2025.02.003_bib0006","doi-asserted-by":"crossref","first-page":"492","DOI":"10.12968\/jowc.2021.30.6.492","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a 10-year experience in a burns unit","volume":"30","author":"Houschyar","year":"2021","journal-title":"J Wound Care"},{"key":"10.1016\/j.jpra.2025.02.003_bib0007","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: An update","volume":"16","author":"Dodiuk-Gad","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0008","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2332\/allergolint.10-RAI-0261","article-title":"Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"59","author":"Chung","year":"2010","journal-title":"Allergology Int"},{"key":"10.1016\/j.jpra.2025.02.003_bib0009","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jpra.2025.02.003_bib0011","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1542\/peds.2008-1923","article-title":"Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis","volume":"123","author":"Levi","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpra.2025.02.003_bib0012","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/epi.12217","article-title":"HLA - B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese","volume":"54","author":"Cheung","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpra.2025.02.003_bib0013","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0014","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients \u2013 Treatment and outcome","volume":"65","author":"Yamane","year":"2016","journal-title":"Allergology Int"},{"key":"10.1016\/j.jpra.2025.02.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2780272","article-title":"Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients","volume":"2018","author":"Sukasem","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jpra.2025.02.003_bib0016","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpra.2025.02.003_bib0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/bjd\/ljae321","article-title":"Recent progress in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: Diagnostic criteria, pathogenesis and treatment","volume":"192","author":"Hama","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0018","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: Comparison with case\u2013control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpra.2025.02.003_bib0019","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/tx5005248","article-title":"Systems pharmacological analysis of drugs inducing Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"28","author":"Hur","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.110749","article-title":"A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population","volume":"79","author":"Patel","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0022","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions: A nationwide population-based study in taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jpra.2025.02.003_bib0023","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.jpra.2025.02.003_bib0024","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000444798","article-title":"Allergic reactions to metamizole: Immediate and delayed responses","volume":"169","author":"Blanca-L\u00f3pez","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0025","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/cea.13689","article-title":"Metamizole-induced reactions as a paradigm of drug hypersensitivity: Non-allergic reactions, anaphylaxis, and delayed-type allergy","volume":"50","author":"Trautmann","year":"2020","journal-title":"Clin Experimental Allergy"},{"key":"10.1016\/j.jpra.2025.02.003_bib0026","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0027","article-title":"Dipyrone (metamizole)-induced Stevens-Johnson syndrome","author":"S","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jpra.2025.02.003_bib0028","doi-asserted-by":"crossref","first-page":"832","DOI":"10.5336\/medsci.2010-18328","article-title":"Great killer or innocent as any drug: Two case reports presenting rare and life-threatening adverse effects of dipyrone","volume":"32","author":"\u00d6","year":"2012","journal-title":"Turkiye Klinikleri J Med Sci"},{"key":"10.1016\/j.jpra.2025.02.003_bib0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jpra.2025.02.003_bib0030","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1067\/mjd.2003.107","article-title":"Lupus-associated toxic epidermal necrolysis: A novel manifestation of lupus?","volume":"48","author":"Mandelcorn","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0031","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaip.2018.07.033","article-title":"Mycoplasma-Induced toxic epidermal necrolysis with severe mucositis","volume":"7","author":"Liu","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0032","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjd.19458","article-title":"Diagnosis of mycoplasma aetiology in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"184","author":"Russell","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0033","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jaad.2021.04.066","article-title":"Mycoplasma-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis: Case-control analysis of a cohort managed in a specialized center","volume":"86","author":"Liew","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0034","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.burns.2013.03.011","article-title":"27 years of a single burn centre experience with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: Analysis of mortality risk for causative agents","volume":"39","author":"Weinand","year":"2013","journal-title":"Burns"},{"key":"10.1016\/j.jpra.2025.02.003_bib0035","first-page":"625","article-title":"Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy","volume":"13","author":"Paulmann","year":"2015","journal-title":"J Deutsche Derma Gesell"},{"key":"10.1016\/j.jpra.2025.02.003_bib0036","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/ijd.IJD_671_21","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: 11-year demographic clinical and prognostic characteristics","volume":"67","author":"Acar","year":"2022","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jpra.2025.02.003_bib0037","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"}],"container-title":["JPRAS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352587825000257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352587825000257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:05:02Z","timestamp":1792764302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352587825000257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":37,"alternative-id":["S2352587825000257"],"URL":"https:\/\/doi.org\/10.1016\/j.jpra.2025.02.003","relation":{},"ISSN":["2352-5878"],"issn-type":[{"value":"2352-5878","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stevens\u2013Johnson Syndrome and Toxic Epidermal Necrolysis: A 15-year Regional Burn Center Experience","name":"articletitle","label":"Article Title"},{"value":"JPRAS Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpra.2025.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic Surgeons.","name":"copyright","label":"Copyright"}]}}